Early Prostate Cancer: Predicting Treatment Response
Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response
Sponsor: Cedars-Sinai Medical Center
Listed as NCT03770351, this observational or N/A phase trial focuses on Prostate Cancer and remains ongoing. Sponsored by Cedars-Sinai Medical Center, it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — May 2023 [monthly]
Recruiting
-
May 2021 — Dec 2021 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting
-
May 2019 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Recruiting
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cedars-Sinai Medical Center
- University of California, Irvine
- University of California, Los Angeles
- VA Long Beach Healthcare System
- VA Medical Center-West Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .